North America Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity
North America digital biomarkers market is expected to grow by 35.8% annually in the forecast period and reach $6,747.2 million by 2030 driven by rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare amid COVID-19 epidemic.
Highlighted with 32 tables and 63 figures, this 139-page report “North America Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
Based on System Component, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Data Collection Tools
Based on Therapeutic Area, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Cardiovascular Diseases
Neurodegenerative Disorders
Psychiatric Disorders
Chronic Pain
Gastrointestinal Diseases
Diabetes
Respiratory Conditions
Other Diseases
Based on Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America digital biomarkers market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Actigraph LLC
Akili Interactive Labs
AliveCor Inc
Altoida Inc
Amgen Inc
Bayer AG
Biogen Inc
Cambridge Cognition Plc
Eli Lilly and Company
Evidation Health, Inc.
F. Hoffmann-La Roche Ltd
Fitbit Inc
GlaxoSmithKline Plc
Happify Health
Human API
IXICO Plc
Koninklijke Philips N.V.
Medical Care Corporation
Medopad Ltd
Mindstrong Health
Neurotrack Technology, Inc
Novartis International AG
Pfizer Inc.
Quanterix Corporation
Sanofi S.A.
The Takeda Pharmaceuticals Company Limited
Verily Life Sciences
Winterlight Labs Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Highlighted with 32 tables and 63 figures, this 139-page report “North America Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Fiver Forces
Based on System Component, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Data Collection Tools
- Digital Platforms
- Mobile Apps
- Desktop-based Software
- Wearables
- Biosensors
Based on Therapeutic Area, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Cardiovascular Diseases
Neurodegenerative Disorders
- Parkinson’s Disease
- Multiple Sclerosis
- Alzheimer’s Disease
Psychiatric Disorders
Chronic Pain
Gastrointestinal Diseases
Diabetes
Respiratory Conditions
Other Diseases
Based on Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Wellness
- Disease Diagnosis
- Personalised Medication
- Drug Discovery and Development
- Novel Digital Biomarkers
- Original Digital Biomarkers
- Approved Digital Biomarkers
- Biopharmaceutical Companies & Labs
- Healthcare Providers
- Insurance Payers
- U.S.
- Canada
- Mexico
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America digital biomarkers market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Actigraph LLC
Akili Interactive Labs
AliveCor Inc
Altoida Inc
Amgen Inc
Bayer AG
Biogen Inc
Cambridge Cognition Plc
Eli Lilly and Company
Evidation Health, Inc.
F. Hoffmann-La Roche Ltd
Fitbit Inc
GlaxoSmithKline Plc
Happify Health
Human API
IXICO Plc
Koninklijke Philips N.V.
Medical Care Corporation
Medopad Ltd
Mindstrong Health
Neurotrack Technology, Inc
Novartis International AG
Pfizer Inc.
Quanterix Corporation
Sanofi S.A.
The Takeda Pharmaceuticals Company Limited
Verily Life Sciences
Winterlight Labs Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 INTRODUCTION
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF NORTH AMERICA MARKET BY SYSTEM COMPONENT
3.1 Market Overview by System Component
3.2 Data Collection Tools
3.2.1 Digital Platforms
3.2.2 Mobile Apps
3.2.3 Desktop-based Software
3.2.4 Wearables
3.2.5 Biosensors
3.3 Data Integration Systems
4 SEGMENTATION OF NORTH AMERICA MARKET BY THERAPEUTIC AREA
4.1 Market Overview by Therapeutic Area
4.2 Cardiovascular Diseases
4.3 Neurodegenerative Disorders
4.3.1 Parkinson’s Disease
4.3.2 Multiple Sclerosis
4.3.3 Alzheimer’s Disease
4.4 Sleep and Movement Diseases
4.5 Psychiatric Disorders
4.6 Chronic Pain
4.7 Gastrointestinal Diseases
4.8 Diabetes
4.9 Respiratory Conditions
4.10 Other Diseases
5 SEGMENTATION OF NORTH AMERICA MARKET BY APPLICATION
5.1 Market Overview by Application
5.2 Wellness
5.3 Disease Diagnosis
5.4 Personalised Medication
5.5 Drug Discovery and Development
6 SEGMENTATION OF NORTH AMERICA MARKET BY DEVELOPMENT STATUS
6.1 Market Overview by Development Status
6.2 Novel Digital Biomarkers
6.3 Original Digital Biomarkers
6.4 Approved Digital Biomarkers
7 SEGMENTATION OF NORTH AMERICA MARKET BY END USER
7.1 Market Overview by End User
7.2 Biopharmaceutical Companies & Labs
7.3 Healthcare Providers
7.4 Insurance Payers
8 NORTH AMERICA MARKET 2019-2030 BY COUNTRY
8.1 Overview of North America Market
8.2 U.S.
8.3 Canada
8.4 Mexico
9 COMPETITIVE LANDSCAPE
9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
Actigraph LLC
Akili Interactive Labs
AliveCor Inc
Altoida Inc
Amgen Inc
Bayer AG
Biogen Inc
Cambridge Cognition Plc
Eli Lilly and Company
Evidation Health, Inc.
F. Hoffmann-La Roche Ltd
Fitbit Inc
GlaxoSmithKline Plc
Happify Health
Human API
IXICO Plc
Koninklijke Philips N.V.
Medical Care Corporation
Medopad Ltd
Mindstrong Health
Neurotrack Technology, Inc
Novartis International AG
Pfizer Inc.
Quanterix Corporation
Sanofi S.A.
The Takeda Pharmaceuticals Company Limited
Verily Life Sciences
Winterlight Labs Inc.
10 INVESTING IN NORTH AMERICA MARKET: RISK ASSESSMENT AND MANAGEMENT
10.1 Risk Evaluation of North America Market
10.2 Critical Success Factors (CSFs)
Related Reports and Products
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF NORTH AMERICA MARKET BY SYSTEM COMPONENT
3.1 Market Overview by System Component
3.2 Data Collection Tools
3.2.1 Digital Platforms
3.2.2 Mobile Apps
3.2.3 Desktop-based Software
3.2.4 Wearables
3.2.5 Biosensors
3.3 Data Integration Systems
4 SEGMENTATION OF NORTH AMERICA MARKET BY THERAPEUTIC AREA
4.1 Market Overview by Therapeutic Area
4.2 Cardiovascular Diseases
4.3 Neurodegenerative Disorders
4.3.1 Parkinson’s Disease
4.3.2 Multiple Sclerosis
4.3.3 Alzheimer’s Disease
4.4 Sleep and Movement Diseases
4.5 Psychiatric Disorders
4.6 Chronic Pain
4.7 Gastrointestinal Diseases
4.8 Diabetes
4.9 Respiratory Conditions
4.10 Other Diseases
5 SEGMENTATION OF NORTH AMERICA MARKET BY APPLICATION
5.1 Market Overview by Application
5.2 Wellness
5.3 Disease Diagnosis
5.4 Personalised Medication
5.5 Drug Discovery and Development
6 SEGMENTATION OF NORTH AMERICA MARKET BY DEVELOPMENT STATUS
6.1 Market Overview by Development Status
6.2 Novel Digital Biomarkers
6.3 Original Digital Biomarkers
6.4 Approved Digital Biomarkers
7 SEGMENTATION OF NORTH AMERICA MARKET BY END USER
7.1 Market Overview by End User
7.2 Biopharmaceutical Companies & Labs
7.3 Healthcare Providers
7.4 Insurance Payers
8 NORTH AMERICA MARKET 2019-2030 BY COUNTRY
8.1 Overview of North America Market
8.2 U.S.
8.3 Canada
8.4 Mexico
9 COMPETITIVE LANDSCAPE
9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
Actigraph LLC
Akili Interactive Labs
AliveCor Inc
Altoida Inc
Amgen Inc
Bayer AG
Biogen Inc
Cambridge Cognition Plc
Eli Lilly and Company
Evidation Health, Inc.
F. Hoffmann-La Roche Ltd
Fitbit Inc
GlaxoSmithKline Plc
Happify Health
Human API
IXICO Plc
Koninklijke Philips N.V.
Medical Care Corporation
Medopad Ltd
Mindstrong Health
Neurotrack Technology, Inc
Novartis International AG
Pfizer Inc.
Quanterix Corporation
Sanofi S.A.
The Takeda Pharmaceuticals Company Limited
Verily Life Sciences
Winterlight Labs Inc.
10 INVESTING IN NORTH AMERICA MARKET: RISK ASSESSMENT AND MANAGEMENT
10.1 Risk Evaluation of North America Market
10.2 Critical Success Factors (CSFs)
Related Reports and Products
LIST OF TABLES
Table 1. Snapshot of North America Digital Biomarkers Market, 2019-2030
Table 2. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples
Table 3. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets, 2019-2030
Table 4. World Mobile Data Traffic by Deployment Mode, 2019-2030, EB/year
Table 5. World Mobile Data Traffic by Device, 2019-2030, EB/year
Table 6. Current Challenges of Digital Biomarkers in Medical Settings
Table 7. Main Product Trends and Market Opportunities in North America Digital Biomarkers Market
Table 8. North America Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 9. North America Digital Biomarkers Market: Data Collection Tools by Type, 2019-2030, $ mn
Table 10. North America Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 11. North America Digital Biomarkers Market: Neurodegenerative Disorders by Type, 2019-2030, $ mn
Table 12. North America Digital Biomarkers Market by Application, 2019-2030, $ mn
Table 13. North America Digital Biomarkers Market by Development Status, 2019-2030, $ mn
Table 14. North America Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 15. North America Digital Biomarkers Market by Country, 2019-2030, $ mn
Table 16. U.S. Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 17. U.S. Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 18. U.S. Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 19. Canada Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 20. Canada Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 21. Canada Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 22. Mexico Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 23. Mexico Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 24. Mexico Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 25. Breakdown of North America Market by Key Vendor, 2019, %
Table 26. Actigraph LLC: Company Snapshot
Table 27. Actigraph LLC: Business Segmentation
Table 28. Actigraph LLC: Product Portfolio
Table 29. Actigraph LLC: Revenue, 2016-2018, $ mn
Table 30. Actigraph LLC: Recent Developments
Table 31. Risk Evaluation for Investing in North America Market, 2019-2030
Table 32. Critical Success Factors and Key Takeaways
Table 1. Snapshot of North America Digital Biomarkers Market, 2019-2030
Table 2. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples
Table 3. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets, 2019-2030
Table 4. World Mobile Data Traffic by Deployment Mode, 2019-2030, EB/year
Table 5. World Mobile Data Traffic by Device, 2019-2030, EB/year
Table 6. Current Challenges of Digital Biomarkers in Medical Settings
Table 7. Main Product Trends and Market Opportunities in North America Digital Biomarkers Market
Table 8. North America Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 9. North America Digital Biomarkers Market: Data Collection Tools by Type, 2019-2030, $ mn
Table 10. North America Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 11. North America Digital Biomarkers Market: Neurodegenerative Disorders by Type, 2019-2030, $ mn
Table 12. North America Digital Biomarkers Market by Application, 2019-2030, $ mn
Table 13. North America Digital Biomarkers Market by Development Status, 2019-2030, $ mn
Table 14. North America Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 15. North America Digital Biomarkers Market by Country, 2019-2030, $ mn
Table 16. U.S. Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 17. U.S. Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 18. U.S. Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 19. Canada Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 20. Canada Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 21. Canada Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 22. Mexico Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 23. Mexico Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 24. Mexico Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 25. Breakdown of North America Market by Key Vendor, 2019, %
Table 26. Actigraph LLC: Company Snapshot
Table 27. Actigraph LLC: Business Segmentation
Table 28. Actigraph LLC: Product Portfolio
Table 29. Actigraph LLC: Revenue, 2016-2018, $ mn
Table 30. Actigraph LLC: Recent Developments
Table 31. Risk Evaluation for Investing in North America Market, 2019-2030
Table 32. Critical Success Factors and Key Takeaways
LIST OF FIGURES
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. North America Digital Biomarkers Market, 2019-2030, $ mn
Figure 6. Category and Relationship of Traditional Biomarkers and Digital Biomarkers
Figure 7. Benefits and Challenges of Digital Biomarkers
Figure 8. North America Biomarkers Market, 2019-2030, $ mn
Figure 9. Share of Digital Biomarkers in Total Biomarkers Market, 2019-2030
Figure 10. Impact of COVID-19 on Business
Figure 11. Primary Drivers and Impact Factors of North America Digital Biomarkers Market
Figure 12. World 5G Traffic, 2019-2030, EB/year
Figure 13. Primary Restraints and Impact Factors of North America Digital Biomarkers Market
Figure 14. Data Security Risk in Various User Groups of Digital Biomarkers
Figure 15. Pathway to Regulatory Approval of Digital Biomarkers
Figure 16. Investment Opportunity Analysis
Figure 17. Porter’s Fiver Forces Analysis of North America Digital Biomarkers Market
Figure 18. Breakdown of North America Digital Biomarkers Market by System Component, 2019-2030, % of Revenue
Figure 19. North America Addressable Market Cap in 2020-2030 by System Component, Value ($ mn) and Share (%)
Figure 20. North America Digital Biomarkers Market: Data Collection Tools, 2019-2030, $ mn
Figure 21. North America Digital Biomarkers Market: Digital Platforms, 2019-2030, $ mn
Figure 22. North America Digital Biomarkers Market: Mobile Apps, 2019-2030, $ mn
Figure 23. North America Digital Biomarkers Market: Desktop-based Software, 2019-2030, $ mn
Figure 24. North America Digital Biomarkers Market: Wearables, 2019-2030, $ mn
Figure 25. North America Digital Biomarkers Market: Biosensors, 2019-2030, $ mn
Figure 26. North America Digital Biomarkers Market: Data Integration Systems, 2019-2030, $ mn
Figure 27. Breakdown of North America Digital Biomarkers Market by Therapeutic Area, 2019-2030, % of Sales Revenue
Figure 28. North America Addressable Market Cap in 2020-2030 by Therapeutic Area, Value ($ mn) and Share (%)
Figure 29. North America Digital Biomarkers Market: Cardiovascular Diseases, 2019-2030, $ mn
Figure 30. North America Digital Biomarkers Market: Neurodegenerative Disorders, 2019-2030, $ mn
Figure 31. North America Digital Biomarkers Market: Parkinson’s Disease, 2019-2030, $ mn
Figure 32. North America Digital Biomarkers Market: Multiple Sclerosis, 2019-2030, $ mn
Figure 33. North America Digital Biomarkers Market: Alzheimer’s Disease, 2019-2030, $ mn
Figure 34. North America Digital Biomarkers Market: Sleep and Movement Diseases, 2019-2030, $ mn
Figure 35. North America Digital Biomarkers Market: Psychiatric Disorders, 2019-2030, $ mn
Figure 36. North America Digital Biomarkers Market: Chronic Pain, 2019-2030, $ mn
Figure 37. North America Digital Biomarkers Market: Gastrointestinal Diseases, 2019-2030, $ mn
Figure 38. North America Digital Biomarkers Market: Diabetes, 2019-2030, $ mn
Figure 39. North America Digital Biomarkers Market: Respiratory Conditions, 2019-2030, $ mn
Figure 40. North America Digital Biomarkers Market: Other Diseases, 2019-2030, $ mn
Figure 41. Breakdown of North America Digital Biomarkers Market by Application, 2019-2030, % of Sales Revenue
Figure 42. North America Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)
Figure 43. North America Digital Biomarkers Market: Wellness, 2019-2030, $ mn
Figure 44. North America Digital Biomarkers Market: Disease Diagnosis, 2019-2030, $ mn
Figure 45. North America Digital Biomarkers Market: Personalised Medication, 2019-2030, $ mn
Figure 46. North America Digital Biomarkers Market: Drug Discovery and Development, 2019-2030, $ mn
Figure 47. Classification of Digital Biomarkers by Development Status
Figure 48. Breakdown of North America Digital Biomarkers Market by Development Status, 2019-2030, % of Revenue
Figure 49. North America Addressable Market Cap in 2020-2030 by Development Status, Value ($ mn) and Share (%)
Figure 50. North America Digital Biomarkers Market: Novel Digital Biomarkers, 2019-2030, $ mn
Figure 51. North America Digital Biomarkers Market: Original Digital Biomarkers, 2019-2030, $ mn
Figure 52. North America Digital Biomarkers Market: Approved Digital Biomarkers, 2019-2030, $ mn
Figure 53. Breakdown of North America Digital Biomarkers Market by End User, 2019-2030, % of Revenue
Figure 54. North America Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)
Figure 55. North America Digital Biomarkers Market: Biopharmaceutical Companies & Labs, 2019-2030, $ mn
Figure 56. North America Digital Biomarkers Market: Healthcare Providers, 2019-2030, $ mn
Figure 57. North America Digital Biomarkers Market: Insurance Payers, 2019-2030, $ mn
Figure 58. Breakdown of North America Digital Biomarkers Market by Country, 2019 and 2030, % of Revenue
Figure 59. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 60. U.S. Digital Biomarkers Market, 2019-2030, $ mn
Figure 61. Canada Digital Biomarkers Market, 2019-2030, $ mn
Figure 62. Digital Biomarkers Market in Mexico, 2015-2030, $ mn
Figure 63. Growth Stage of North America Digital Biomarkers Industry over the Forecast Period
COMPANIES MENTIONED
Actigraph LLC
Akili Interactive Labs
AliveCor Inc
Altoida Inc
Amgen Inc
Bayer AG
Biogen Inc
Cambridge Cognition Plc
Eli Lilly and Company
Evidation Health, Inc.
F. Hoffmann-La Roche Ltd
Fitbit Inc
GlaxoSmithKline Plc
Happify Health
Human API
IXICO Plc
Koninklijke Philips N.V.
Medical Care Corporation
Medopad Ltd
Mindstrong Health
Neurotrack Technology, Inc
Novartis International AG
Pfizer Inc.
Quanterix Corporation
Sanofi S.A.
The Takeda Pharmaceuticals Company Limited
Verily Life Sciences
Winterlight Labs Inc.
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. North America Digital Biomarkers Market, 2019-2030, $ mn
Figure 6. Category and Relationship of Traditional Biomarkers and Digital Biomarkers
Figure 7. Benefits and Challenges of Digital Biomarkers
Figure 8. North America Biomarkers Market, 2019-2030, $ mn
Figure 9. Share of Digital Biomarkers in Total Biomarkers Market, 2019-2030
Figure 10. Impact of COVID-19 on Business
Figure 11. Primary Drivers and Impact Factors of North America Digital Biomarkers Market
Figure 12. World 5G Traffic, 2019-2030, EB/year
Figure 13. Primary Restraints and Impact Factors of North America Digital Biomarkers Market
Figure 14. Data Security Risk in Various User Groups of Digital Biomarkers
Figure 15. Pathway to Regulatory Approval of Digital Biomarkers
Figure 16. Investment Opportunity Analysis
Figure 17. Porter’s Fiver Forces Analysis of North America Digital Biomarkers Market
Figure 18. Breakdown of North America Digital Biomarkers Market by System Component, 2019-2030, % of Revenue
Figure 19. North America Addressable Market Cap in 2020-2030 by System Component, Value ($ mn) and Share (%)
Figure 20. North America Digital Biomarkers Market: Data Collection Tools, 2019-2030, $ mn
Figure 21. North America Digital Biomarkers Market: Digital Platforms, 2019-2030, $ mn
Figure 22. North America Digital Biomarkers Market: Mobile Apps, 2019-2030, $ mn
Figure 23. North America Digital Biomarkers Market: Desktop-based Software, 2019-2030, $ mn
Figure 24. North America Digital Biomarkers Market: Wearables, 2019-2030, $ mn
Figure 25. North America Digital Biomarkers Market: Biosensors, 2019-2030, $ mn
Figure 26. North America Digital Biomarkers Market: Data Integration Systems, 2019-2030, $ mn
Figure 27. Breakdown of North America Digital Biomarkers Market by Therapeutic Area, 2019-2030, % of Sales Revenue
Figure 28. North America Addressable Market Cap in 2020-2030 by Therapeutic Area, Value ($ mn) and Share (%)
Figure 29. North America Digital Biomarkers Market: Cardiovascular Diseases, 2019-2030, $ mn
Figure 30. North America Digital Biomarkers Market: Neurodegenerative Disorders, 2019-2030, $ mn
Figure 31. North America Digital Biomarkers Market: Parkinson’s Disease, 2019-2030, $ mn
Figure 32. North America Digital Biomarkers Market: Multiple Sclerosis, 2019-2030, $ mn
Figure 33. North America Digital Biomarkers Market: Alzheimer’s Disease, 2019-2030, $ mn
Figure 34. North America Digital Biomarkers Market: Sleep and Movement Diseases, 2019-2030, $ mn
Figure 35. North America Digital Biomarkers Market: Psychiatric Disorders, 2019-2030, $ mn
Figure 36. North America Digital Biomarkers Market: Chronic Pain, 2019-2030, $ mn
Figure 37. North America Digital Biomarkers Market: Gastrointestinal Diseases, 2019-2030, $ mn
Figure 38. North America Digital Biomarkers Market: Diabetes, 2019-2030, $ mn
Figure 39. North America Digital Biomarkers Market: Respiratory Conditions, 2019-2030, $ mn
Figure 40. North America Digital Biomarkers Market: Other Diseases, 2019-2030, $ mn
Figure 41. Breakdown of North America Digital Biomarkers Market by Application, 2019-2030, % of Sales Revenue
Figure 42. North America Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)
Figure 43. North America Digital Biomarkers Market: Wellness, 2019-2030, $ mn
Figure 44. North America Digital Biomarkers Market: Disease Diagnosis, 2019-2030, $ mn
Figure 45. North America Digital Biomarkers Market: Personalised Medication, 2019-2030, $ mn
Figure 46. North America Digital Biomarkers Market: Drug Discovery and Development, 2019-2030, $ mn
Figure 47. Classification of Digital Biomarkers by Development Status
Figure 48. Breakdown of North America Digital Biomarkers Market by Development Status, 2019-2030, % of Revenue
Figure 49. North America Addressable Market Cap in 2020-2030 by Development Status, Value ($ mn) and Share (%)
Figure 50. North America Digital Biomarkers Market: Novel Digital Biomarkers, 2019-2030, $ mn
Figure 51. North America Digital Biomarkers Market: Original Digital Biomarkers, 2019-2030, $ mn
Figure 52. North America Digital Biomarkers Market: Approved Digital Biomarkers, 2019-2030, $ mn
Figure 53. Breakdown of North America Digital Biomarkers Market by End User, 2019-2030, % of Revenue
Figure 54. North America Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)
Figure 55. North America Digital Biomarkers Market: Biopharmaceutical Companies & Labs, 2019-2030, $ mn
Figure 56. North America Digital Biomarkers Market: Healthcare Providers, 2019-2030, $ mn
Figure 57. North America Digital Biomarkers Market: Insurance Payers, 2019-2030, $ mn
Figure 58. Breakdown of North America Digital Biomarkers Market by Country, 2019 and 2030, % of Revenue
Figure 59. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 60. U.S. Digital Biomarkers Market, 2019-2030, $ mn
Figure 61. Canada Digital Biomarkers Market, 2019-2030, $ mn
Figure 62. Digital Biomarkers Market in Mexico, 2015-2030, $ mn
Figure 63. Growth Stage of North America Digital Biomarkers Industry over the Forecast Period
COMPANIES MENTIONED
Actigraph LLC
Akili Interactive Labs
AliveCor Inc
Altoida Inc
Amgen Inc
Bayer AG
Biogen Inc
Cambridge Cognition Plc
Eli Lilly and Company
Evidation Health, Inc.
F. Hoffmann-La Roche Ltd
Fitbit Inc
GlaxoSmithKline Plc
Happify Health
Human API
IXICO Plc
Koninklijke Philips N.V.
Medical Care Corporation
Medopad Ltd
Mindstrong Health
Neurotrack Technology, Inc
Novartis International AG
Pfizer Inc.
Quanterix Corporation
Sanofi S.A.
The Takeda Pharmaceuticals Company Limited
Verily Life Sciences
Winterlight Labs Inc.
